Similar articles

• Dyslipidaemia associated with antiretroviral therapy in HIV-infected patients.

  Calza L, Manfredi R, Chiodo F. Calza L, et al. J Antimicrob Chemother. 2004 Jan;53(1):10-4. doi: 10.1093/jac/dkh013. Epub 2003 Nov 25. J Antimicrob Chemother. 2004. PMID: 14645323 Review.
• Lipid-lowering drugs and changes to diet can make a difference.

  [No authors listed] [No authors listed] TreatmentUpdate. 2001 Aug;13(4):7-9. TreatmentUpdate. 2001. PMID: 11590981 No abstract available.
• Lipid lowering effects of statins and fibrates in the management of HIV dyslipidemias associated with antiretroviral therapy in HIV clinical practice.

  Visnegarwala F, Maldonado M, Sajja P, Minihan JL, Rodriguez-Barradas MC, Ong O, Lahart CJ, Hasan MQ, Balasubramanyam A, White AC Jr. Visnegarwala F, et al. J Infect. 2004 Nov;49(4):283-90. doi: 10.1016/j.jinf.2003.09.006. J Infect. 2004. PMID: 15474625
• Fibrates or statins and lipid plasma levels in 245 patients treated with highly active antiretroviral therapy. Aquitaine Cohort, France, 1999-2001.

  Bonnet F, Balestre E, Thiébaut R, Mercié P, Dupon M, Morlat P, Dabis F; Groupe d'Epidémiologie Clinique du SIDA en Aquitaine (GECSA). Bonnet F, et al. HIV Med. 2004 May;5(3):133-9. doi: 10.1111/j.1468-1293.2004.00200.x. HIV Med. 2004. PMID: 15139977
• Management of dyslipidaemia in HIV-infected patients receiving antiretroviral therapy.

  Martínez E, Tuset M, Milinkovic A, Miró JM, Gatell JM. Martínez E, et al. Antivir Ther. 2004 Oct;9(5):649-63. Antivir Ther. 2004. PMID: 15535403 Review.